Who We are
Advantagene (d.b.a. Candel Therapeutics) is a Boston-area privately held biopharmaceutical company. We are committed to saving, extending and improving the lives of cancer patients and their families through the development and commercialization of innovative and personalized cancer immunotherapies. At the forefront of these efforts is our proprietary Gene Mediated Cytotoxic Immunotherapy™ (GMCI™), a platform technology designed to stimulate a patient’s immune system to naturally fight against his or her cancer. GMCI™is a novel and versatile technology that can be applied to a variety of solid tumors. It is based on a relatively low cost and readily available “off-the-shelf” viral vector product (aglatimagene besadenovec; a.k.a. AdV-tk) that generates a powerful patient-specific anti-tumor immune response in-vivo. With hundreds of patients dosed over more than a decade, GMCI™has an established safety profile lacking the numerous side effects typically associated with cancer therapies.
GMCI™is synergistic with standard of care radiation, surgery, and some chemotherapy due to multiple factors:
A unique mechanism of action
The ability to focus the immune system toward a patient’s own unique cancer
GMCI’s safety and benign side effect profile
As a result, we believe that GMCI™can improve patient outcomes without interrupting therapies currently trusted by physicians and patients. The results of our early studies, working with the support of esteemed and influential leaders in the oncology community, are promising. GMCI™has several unique characteristics that provide benefits to patients, payors and providers that few other, if any, cancer therapies can deliver.
Our Mission is to save, extend and improve the lives of cancer patients and their families. We see every day and dollar spent through the eyes of a patient and their family. Advantagene has GMCI™ clinical cancer studies in prostate, brain, lung and pancreas, with notable clinical results to date. Additionally, we are also researching the potential use of GMCI in other solid tumor indications.